What question did this study set out to answer?

The aim is to develop patient-derived liver cancer organoids to enhance diagnostics and personalize therapies.

March 18, 2026Cellular OncologyOpen Access

Single-cell transcriptomic mapping of patient-derived primary liver cancer organoids reveals molecular subtypes and guides precision drug targeting

View Full Paper

Ask AI

Bookmark

Authors

This research identifies molecular subtypes of liver cancer organoids, highlighting implications for precision therapies in patients.

The aim is to develop patient-derived liver cancer organoids to enhance diagnostics and personalize therapies.
Generated organoids from three liver cancer subtypes
Performed whole exome sequencing and RNA sequencing
Conducted drug screening targeting specific molecular pathways
Used single-cell RNA sequencing to map cell populations
Organoids maintained genetic fidelity to parental tumors
Distinct cell populations identified in different subtype organoids
Lipid metabolism was enriched in HCC, aiding growth inhibition with rosuvastatin
Tumor migration pathways were upregulated in ICC, targeted by pemigatinib
Mitochondrial function enhanced in CHC, impaired by regorafenib

Dai et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark